Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
03 Août 2023 - 10:12PM
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage
biopharmaceutical company translating genetic insights into the
development of therapies for central nervous system (CNS) disorders
characterized by neuronal excitation-inhibition imbalance, today
announced that management will participate at the 2023 Wedbush
PacGrow Healthcare Conference on Wednesday, August 9, 2023 at
9:30a.m. ET on the panel David vs. Goliath - How Can Orphan
Epilepsy Development Accelerate and Broaden its Reach? Please
contact your Wedbush representative for details about how to
participate.
About PraxisPraxis Precision Medicines is a
clinical-stage biopharmaceutical company translating insights from
genetic epilepsies into the development of therapies for CNS
disorders characterized by neuronal excitation-inhibition
imbalance. Praxis is applying genetic insights to the discovery and
development of therapies for rare and more prevalent neurological
disorders through our proprietary small molecule platform,
Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™,
using our understanding of shared biological targets and circuits
in the brain. Praxis has established a diversified, multimodal CNS
portfolio including multiple programs across movement disorders and
epilepsy, with four clinical-stage product candidates. For more
information, please visit www.praxismedicines.com and follow
us on Facebook, LinkedIn and Twitter.
Investor Contact
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Media Contact
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388
Praxis Precision Medicines (NASDAQ:PRAX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Praxis Precision Medicines (NASDAQ:PRAX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024